@phdthesis{oai:soar-ir.repo.nii.ac.jp:02000285,
 author = {曽根原, 圭},
 month = {Mar},
 note = {雑誌に発表。 / Thoracic Cancer 10(9) :1805-1811(2020); doi:10.1111/1759-7714.13150. ©　2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd 1805 This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium,provided the original work is properly cited and is not used for commercial purposes., Thesis, 曽根原 圭. The efficacy of amrubicin third-line chemotherapy in patients with relapsed　extensive-disease small-cell lung cancer: A retrospective and historical study in a single institute (再発進展型小細胞肺癌の症例に対する3次化学療法としてのアムルビシンの有効性（単施設における後方視的な研究）. 信州大学, 2021, 博士論文. 博士（医学）, 甲第1230号, 令和03年03月31日授与.},
 school = {信州大学(Shinshu university)},
 title = {The efficacy of amrubicin third-line chemotherapy in patients with relapsed　extensive-disease small-cell lung cancer: A retrospective and historical study in a single institute (再発進展型小細胞肺癌の症例に対する3次化学療法としてのアムルビシンの有効性（単施設における後方視的な研究）},
 year = {2021}
}